Biosensors

Biosensors: receives CE Mark Approval for BioMatric NeoFlex, the latest addition to the BioMatrix family of drug-eluting stents (DES). This latest product offers an improved stent delivery system, and has a lower lesion entry profile than its predecessor, BioMatrix Flex. Mgt believes Neoflex will enable the group to retain its position in biodegradable polymer stent technology. NeoFlex will be rolled out in all CE Mark global mkts over the coming months. The stock trades at 14.7x P/E, vs HK-listed peer Microport at 16.9x.